Patents by Inventor Louis Boon
Louis Boon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240111517Abstract: An example operation may include one or more of receiving a software update at a transport of a subset of transports, validating the software update based on one or more of: a period of time when the software update is in use, and a number of utilizations of the software update by the subset of the transports, propagating the software update based on the validating, to a further subset of transports, wherein the further subset of the transports is larger than the subset of the transports.Type: ApplicationFiled: December 14, 2023Publication date: April 4, 2024Applicant: TOYOTA MOTOR NORTH AMERICA, INC.Inventors: Louis Brugman, Devang H. Parekh, Wilson-Boon Siang Khoo
-
Publication number: 20230242646Abstract: The disclosure describes a humanized antibody that can bind an extracellular part of human CD89 (human Fc?RI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells. The disclosure also describes the use of such antibodies in combating certain diseases.Type: ApplicationFiled: April 21, 2021Publication date: August 3, 2023Inventors: Petrus Johannes Simons, Marcel Theodorus Den Hartog, Louis Boon
-
Publication number: 20230052646Abstract: The invention discloses an antibody that binds an extracellular part of human HVEM on human HVEM-expressing cells, that prevents binding of BTLA to HVEM when the antibody is bound to said extracellular part of HVEM, wherein said antibody displaces BTLA bound to said extracellular part of HVEM. The invention also discloses the use of such an antibody in combating certain diseases.Type: ApplicationFiled: December 24, 2020Publication date: February 16, 2023Inventors: Louis Boon, Petrus Johannes Simons, Marcel Theodorus Den Hartog
-
Publication number: 20210388084Abstract: The invention discloses an antibody that can bind an extra-cellular part of human CD89 (human Fc?RI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells and that induces less cell death in said human CD89 expressing cells when compared to the antibody MIP8a. The invention also disclosed the use of such antibodies in combating certain diseases.Type: ApplicationFiled: October 24, 2019Publication date: December 16, 2021Inventors: Petrus Johannes SIMONS, Marcel Theodorus DEN HARTOG, Louis BOON
-
Patent number: 10717785Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.Type: GrantFiled: February 23, 2018Date of Patent: July 21, 2020Assignee: BROTEIO PHARMA B.V.Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Publication number: 20200199525Abstract: The invention provide a method for reducing the amount of acidic species and/or increasing the amount of basic species in a composition comprising a recombinant protein or for increasing the specific production rate of mammalian cells expressing a recombinant protein to simplify subsequent clarification and purification of the recombinant protein, said method comprising culturing mammalian cells expressing said recombinant protein in a cell culture medium comprising citrulline.Type: ApplicationFiled: June 8, 2018Publication date: June 25, 2020Applicant: Polpharma Biologics S.A.Inventors: Louis Boon, Lenneke De Winter, Tomasz Sitar
-
Publication number: 20190202928Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: March 13, 2019Publication date: July 4, 2019Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
-
Patent number: 10273307Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: GrantFiled: September 11, 2017Date of Patent: April 30, 2019Assignees: Biocerox Products B.V., Janssen Pharmaceuticals, Inc.Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
-
Publication number: 20180319895Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.Type: ApplicationFiled: February 23, 2018Publication date: November 8, 2018Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Publication number: 20180273632Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: May 22, 2018Publication date: September 27, 2018Inventors: Petrus Johannes Simons, Louis Boon
-
Patent number: 9944717Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.Type: GrantFiled: May 22, 2014Date of Patent: April 17, 2018Assignee: Broteio Pharma B.V.Inventors: Cornelis Erik Hack, Cafer Yildiz, Louis Boon, Petrus Johannes Simons
-
Publication number: 20170369586Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: September 11, 2017Publication date: December 28, 2017Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
-
Patent number: 9790281Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: GrantFiled: March 20, 2014Date of Patent: October 17, 2017Assignees: BiocerOX Products, B.V., Janssen Pharmaceuticals, Inc.Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
-
Publication number: 20170051069Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: August 25, 2016Publication date: February 23, 2017Inventors: Petrus Johannes Simons, Louis Boon
-
Patent number: 9475880Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: GrantFiled: September 13, 2012Date of Patent: October 25, 2016Assignees: Biocerox Products, B.V., Janssen Pharmaceuticals, Inc.Inventors: Petrus Johannes Simons, Louis Boon
-
Publication number: 20160108134Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury. Disease.Type: ApplicationFiled: May 22, 2014Publication date: April 21, 2016Inventors: CORNELIS ERIK HACK, CAFER YILDIZ, LOUIS BOON, PETRUS JOHANNES SIMONS
-
Publication number: 20150132288Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: September 13, 2012Publication date: May 14, 2015Applicant: BiocerOX Products B.V.Inventors: Petrus Johannes Simons, Louis Boon
-
Publication number: 20140377284Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.Type: ApplicationFiled: March 20, 2014Publication date: December 25, 2014Applicants: JANSSEN PHARMACEUTICALS, INC., BIOCEROX PRODUCTS B.V.Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
-
Publication number: 20070009517Abstract: Methods for inducing tolerance to a transplant in a subject are disclosed. The methods comprise administering multiple doses of a therapeutically effective amount of a CD40 antagonist alone or in combination with a CD86 antagonist, wherein the first dose of the antagonist is given before or at the time of transplantation; and administering multiple doses of a therapeutically effective amount of an immunosuppressive drug, wherein the first dose of the immunosuppressive drug is given at least several days after transplantation.Type: ApplicationFiled: August 25, 2004Publication date: January 11, 2007Inventors: Mark De Boer, Louis Boon
-
Publication number: 20050214871Abstract: The invention relates to the field of immunology, gene therapy, and medicine. More specifically, the invention relates to the identification of a molecule capable of interacting with a soluble and/or cell-bound form of CD163 and, as a result of the interaction, an immune response is either instigated or suppressed in an organism. Furthermore, it relates to the preparation of a pharmaceutical composition including the molecule and/or antagonist I and/or agonist I thereof, and/or an isolated CD163 and/or an antagonist II or agonist II thereof, for the therapeutic or prophylactic treatment of an individual with an immune response disorder, e.g., inflammation, cancer, or infection.Type: ApplicationFiled: November 23, 2004Publication date: September 29, 2005Inventors: Louis Boon, Petrus Simons, David Speijer, Ruprecht Neerven